The Narrative of a Patient with Leptin Receptor Deficiency: Personalized Medicine for a Rare Genetic Obesity Disorder.
Case report
Genetic obesity
Leptin receptor
Leptin-melanocortin pathway
MC4R agonists
Setmelanotide
Targeted treatment
Journal
Obesity facts
ISSN: 1662-4033
Titre abrégé: Obes Facts
Pays: Switzerland
ID NLM: 101469429
Informations de publication
Date de publication:
2023
2023
Historique:
received:
25
01
2023
accepted:
05
06
2023
medline:
30
10
2023
pubmed:
3
7
2023
entrez:
2
7
2023
Statut:
ppublish
Résumé
Leptin receptor (LEPR) deficiency is a rare genetic disorder that affects the body's ability to regulate appetite and weight. For patients and their families, the disorder seriously disrupts daily life; however, little is published about this impact. We here report the experiences of a 10.5-year-old girl with leptin receptor deficiency and her family. The diagnosis of this rare genetic obesity had a deep impact on the life of the child and her family. It led to a better understanding of the cause of the impaired appetite regulation and early-onset obesity with subsequently less judgement by others and improved cooperation of their social network and school on maintaining a healthy lifestyle for this girl. A strict eating regimen and lifestyle measures resulted in the first year after diagnosis in a significantly decreased body mass index (BMI), followed by BMI stabilization, still categorized as obesity class three. However, the troublesome challenge of how to manage the disruptive behaviour due to hyperphagia remained. Eventually, due to treatment with targeted pharmacotherapy, i.e., melanocortin-4 receptor agonists, her BMI continued to decrease due to resolving hyperphagia. The daily routine of the family and the atmosphere at home positively changed as they were no longer dominated by the food-focused behaviour of the child and the adherence to the strict eating regimen. This case report demonstrates the importance and impact of a rare genetic obesity disorder diagnosis in a family. Additionally, it highlights the value of genetic testing in patients with a high suspicion of a genetic obesity disorder as it can eventually lead to personalized treatment, such as guidance by specialized healthcare professionals and educated caregivers or targeted pharmacotherapy.
Identifiants
pubmed: 37393902
pii: 000531529
doi: 10.1159/000531529
pmc: PMC10601614
doi:
Substances chimiques
Receptors, Leptin
0
Leptin
0
Receptor, Melanocortin, Type 4
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
514-518Informations de copyright
© 2023 The Author(s). Published by S. Karger AG, Basel.
Références
Lancet Diabetes Endocrinol. 2020 Dec;8(12):960-970
pubmed: 33137293
Nat Med. 2018 May;24(5):551-555
pubmed: 29736023
J Clin Endocrinol Metab. 1997 Sep;82(9):2904-10
pubmed: 9284717
Obesity (Silver Spring). 2014 Feb;22 Suppl 1:S1-S17
pubmed: 24574081
Eur J Endocrinol. 2020 Jan;182(1):47-56
pubmed: 31658438
iScience. 2023 Feb 14;26(3):106199
pubmed: 36876127
Med Care. 2001 Aug;39(8):800-12
pubmed: 11468499
Cell Metab. 2018 Jul 03;28(1):23-32.e3
pubmed: 29861388
Clin Obes. 2021 Dec;11(6):e12481
pubmed: 34291582
BMJ Case Rep. 2017 Sep 25;2017:
pubmed: 28951511
Adv Ther. 2022 Apr;39(4):1772-1783
pubmed: 35192151